Login
$SNDX
$9.13 -$0.32 (3.39%) Live

$SNDX SEC Filings

Filed On Filing
12 Nov 2026 Form 4
12 Nov 2026 Form 3: Ondrey Aaron, Chief Financial Officer

No securities owned

10 Nov 2026 SCHEDULE 13G
02 Nov 2026 10-Q
02 Nov 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase –

30 Oct 2026 Form 4: Podlesak Dennis, Director

Received 8,000 shares by exercise or conversion ($94.5K) · Sold 8,000 shares ($114K)

29 Oct 2026 144
07 Aug 2026 SCHEDULE 13G
04 Aug 2026 10-Q
04 Aug 2026 8-K: Results of Operations and Financial Condition

Total revenue of $73 million in 2Q26, a 92% year-over-year increase –

14 Jul 2026 8-K: Other Events

Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and simil...

09 Jul 2026 Form 4: Metzger Michael A, Director

Received 32,375 shares by exercise or conversion ($207K) · Sold 32,375 shares ($785K) · Acquired 32,375 Stock Option (Right to buy) (Option Exercise/Conversion)

08 Jul 2026 144
12 Jun 2026 Form 4: Botwood Nicholas A.j., Head of R&D, CMO

Received 22,515 shares by exercise or conversion ($311K) · Sold 34,280 shares ($617K) · Acquired 22,515 Stock options (Right to buy) (Option Exercise/Conversion) · 3 more

12 Jun 2026 144
11 Jun 2026 144
10 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

INDENTURE dated as of June 10, 2026 between SYNDAX PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking as...

10 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Adoption Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will become av...

04 Jun 2026 DEFA14A
04 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

Syndax Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), is offering a new series of its Convertible Senior Notes due 2031 (the “Notes”). The Notes will be convertible into cash, shares (“Underlying Shares”) of common stock...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support